American Vanguard (AVD) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Outperformed peers in U.S. markets despite challenging agricultural conditions and global headwinds, with specialty business growth offsetting declines in crop sales.
Implemented business improvement plans, including plant rationalization and headquarters relocation, to drive operating leverage and cost efficiencies.
Continued investment in new product development, targeting 50 launches over five years and $100 million in annualized revenue by 2030.
First half 2026 gross profit increased 3% and adjusted EBITDA rose 21% year-over-year, despite flat sales.
Net loss for Q2 2026 was $9.9 million ($0.34 per share), compared to $849 thousand ($0.03 per share) in Q2 2025, driven by higher interest expense and transformation costs.
Financial highlights
Q2 2026 net sales were $116.8–$117 million, down from $129–$129.3 million in Q2 2025; first half sales were $240–$240.3 million, down 2% year-over-year.
Gross margin was 30% in Q2 2026 (down from 31% prior year), and improved to 30% for the first half (up from 29%).
Adjusted EBITDA for Q2 2026 was $6.6 million (down from $11 million), but up 20–21% year-to-date to $17 million.
Net debt increased to $223.7–$224.7 million due to new term loans and higher working capital.
Cash at quarter-end was $43.9 million, up from $14.5 million in Q2 2025.
Outlook and guidance
Maintaining 2026 adjusted EBITDA guidance of $44–$48 million on sales of $530–$550 million.
Targeting over $600 million in annualized revenue by the second half of 2028, with double-digit EBITDA margins.
Confident in order book and shipment timing for the remainder of 2026.
Management anticipates cost-saving initiatives, including plant optimization and headquarters relocation, to lower costs in the second half.
Plan to reduce net debt over the next two years, positioning for refinancing.
Latest events from American Vanguard
- Directors elected, auditor ratified, and ambitious growth targets set amid market headwinds.AVD
AGM 2026 - Q1 2026 sales up 7%, gross margin 31%, and adjusted EBITDA up 245% amid strong U.S. crop growth.AVD
Q1 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.AVD
Proxy filing - 2025 margins and EBITDA held steady despite lower sales; 2026 targets growth and improved profitability.AVD
Q4 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 2024 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 2024 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 2024